Neurology and Therapy (Feb 2024)

Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY)

  • Fabrizio Vernieri,
  • Luigi Francesco Iannone,
  • Simona Guerzoni,
  • Antonio Russo,
  • Piero Barbanti,
  • Grazia Sances,
  • Sabina Cevoli,
  • Renata Rao,
  • Carlo Lovati,
  • Anna Ambrosini,
  • Carlotta Buzzoni,
  • Federico Battisti,
  • Laura Vatteone,
  • Steffy Martin Luther King,
  • Federico Torelli

DOI
https://doi.org/10.1007/s40120-024-00582-0
Journal volume & issue
Vol. 13, no. 2
pp. 415 – 435

Abstract

Read online

Abstract Background Galcanezumab is approved in the European Union (EU) as migraine prophylaxis in adults with at least four migraine days per month. The aim of this retrospective observational study was to evaluate the long-term effectiveness of galcanezumab on migraine-related burdens and its impact on the use of healthcare resources for migraine prophylaxis in an Italian setting. Methods This retrospective study was conducted in patients with migraine who initiated treatment with galcanezumab for migraine prevention between September 2019 and December 2020. Patient data for monthly migraine days (MMDs) and MMDs with acute medication intake were obtained by medical chart reviews. Information on patient-reported outcomes (using the Migraine Disability Assessment [MIDAS] questionnaire and Headache Impact Test 6 [HIT-6] questionnaire) and on the use of healthcare resources were also collected. The time points of interest were 1, 3, 6, 9, 12 months after the initiation of galcanezumab, and the most recent time point available during follow-up. Results A total of 207 patients were enrolled in the study. Starting from month 3 after treatment initiation, more than half of the patients presented at least a 50% reduction in MMDs, and approximately one-third of non-responders at month 3 became responders at month 6. From month 3 to month 12, MMDs decreased on average by 10 days. Headache impact and disability, as well as migraine-associated health resource utilization decreased significantly during the treatment period. A positive significant association among the three dimensions of clinical burden (MMDs, MIDAS and days of acute medication intake) was also observed. Conclusion The results of this Italian real-world study confirmed that galcanezumab has a rapid onset of effect and provides a long-term response among patients over different migraine-related burdens. The use of healthcare resources was also remarkably reduced.

Keywords